DENVER--(BUSINESS WIRE)-- AstraZeneca (NYSE:AZN) today announced results from a long-term study comparing SYMBICORT ® (budesonide/ formoterol fumarate dihydrate) Inhalation Aerosol 160/4.5 mcg with ...

WILMINGTON, Del.--(BUSINESS WIRE)--Results from a US comparative effectiveness study of two maintenance treatment options for patients with a history of chronic obstructive pulmonary disease (COPD) ...

For patients with COPD, the approved dosage of SYMBICORT is 160/4.5 mcg, 2 inhalations twice daily. The most common adverse events greater than or equal to 3% reported in COPD clinical trials included ...

WILMINGTON, Del.--(BUSINESS WIRE)--AstraZeneca today announced the U.S. Food and Drug Administration (FDA) has approved updates to the SYMBICORT ® (budesonide ...

The studies examined the efficacy of Symbicort pressurized metered dose inhaler (pMDI) 160/4.5mcg vs. formoterol 4.5mcg in reducing COPD exacerbations in adults with moderate to severe COPD. The FDA ...

SYMBICORT 160/4.5 mcg is also indicated for the maintenance treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and emphysema.

LONDON (MarketWatch) -- Drugmaker AstraZeneca said Monday that the U.S. Food and Drug Administration has approved Symbicort 160/4.5 mcg for the twice daily maintenance treatment of airflow obstruction ...

(RTTNews) - The U.S. Food and Drug Administration approved Mylan Pharmaceuticals, Inc.'s generic of Symbicort (budesonide and formoterol fumarate dihydrate) inhalation aerosol. It is the first FDA- ...

The US Food and Drug Administration has approved AstraZeneca's Symbicort inhalation aerosol (80/4.5 mcg) for children aged 6 to 12 years with asthma that is not well controlled with an inhaled ...

Symbicort, which is used to treat chronic obstructive pulmonary disease and asthma, can cause side effects. Mild side effects include nasal congestion and headaches. Serious side effects include ...